# Global research trends in non-coding RNA and intestinal epithelial homeostasis: an integrated bibliometric analysis (2007–2024) **Authors:** Xinxin Wang, Xuan Li, Yongtian Wen, Bochao Yuan, Xudong Tang, Ting Chen PMC · DOI: 10.1186/s41065-025-00560-y · Hereditas · 2025-10-17 ## TL;DR This paper analyzes global research trends on non-coding RNA and intestinal health from 2007 to 2024, identifying key areas and future directions. ## Contribution The study provides a comprehensive bibliometric analysis of non-coding RNA and intestinal epithelial homeostasis research trends. ## Key findings - China and the United States led in publishing research on non-coding RNA and intestinal epithelial homeostasis. - Inflammatory bowel disease is a major focus, while circRNA is an emerging area of interest. - Future research potential lies in ncRNAs related to intestinal stem cells and colitis-associated cancer. ## Abstract Non-coding RNAs regulate gene expression through various mechanisms, playing key roles in life activities. Intestinal epithelial homeostasis (IEH) is a dynamic equilibrium state formed by the interaction of intestinal mucosal barrier, intestinal environment and other factors. There are many recorded documents demonstrating a close relationship between non-coding RNAs and IEH. Therefore, it is significant to retrospectively explore the current status, hotspots and trends of non-coding RNA (ncRNA) and IEH through a bibliometric perspective. We searched the Web of Science (WOS) for studies related to non-coding RNA and intestinal epithelial homeostasis from 1980 to December 2024, then downloaded the data. CiteSpace 6.3.1, VOSviewer 1.6.20, SCImago Graphica and Excel software were used to draw knowledge visualization maps. A total of 667 publications relevant to ncRNA and IEH were included. The publication output and citation counts generally demonstrated an initial increase followed by a subsequent decrease. The publications have received a total of 18,979 citations, with an average of approximately 28 citations per article. China published the most articles, followed by the United States. Keyword analysis indicated that inflammatory bowel disease (IBD), intestinal immunity, and gut microbiota were of high importance. IBD dominates IEH research, yet circRNA is an emerging focus. Exploring ncRNAs in intestinal stem cell and colitis-associated cancer holds great research potential in the future. Multidisciplinary integration is the research trend. Our findings provide a comprehensive knowledge framework for researchers and clinicians aiming to explore ncRNA-based diagnostic and therapeutic strategies for IEH. Our results highlight the need for translational research to validate ncRNA-based diagnostic and therapeutic strategies for gut barrier disorders. The online version contains supplementary material available at 10.1186/s41065-025-00560-y. ## Linked entities - **Diseases:** inflammatory bowel disease (MONDO:0005265) ## Full-text entities - **Genes:** MIR155 (microRNA 155) [NCBI Gene 406947] {aka MIRN155, miRNA155, mir-155}, MIR4435-2HG (MIR4435-2 host gene) [NCBI Gene 541471] {aka AGD2, LINC00978, MIR4435-1HG, MORRBID, lncRNA-AWPPH}, Nlrp3 (NLR family, pyrin domain containing 3) [NCBI Gene 216799] {aka AGTAVPRL, AII/AVP, Cias1, FCAS, FCU, MWS}, MIR222 (microRNA 222) [NCBI Gene 407007] {aka MIRN222, miRNA222, mir-222}, TUG1 (taurine up-regulated 1) [NCBI Gene 55000] {aka LINC00080, NCRNA00080, TI-227H}, HIPK2 (homeodomain interacting protein kinase 2) [NCBI Gene 28996] {aka PRO0593}, CD4 (CD4 molecule) [NCBI Gene 920] {aka CD4mut, IMD79, Leu-3, OKT4D, T4}, SNHG9 (small nucleolar RNA host gene 9) [NCBI Gene 735301] {aka NCRNA00062}, TAFAZZIN (tafazzin, phospholipid-lysophospholipid transacylase) [NCBI Gene 6901] {aka BTHS, CMD3A, EFE, EFE2, G4.5, LVNCX}, NEAT1 (nuclear paraspeckle assembly transcript 1) [NCBI Gene 283131] {aka LINC00084, NCRNA00084, TP53LC15, TncRNA, VINC}, MIR301A (microRNA 301a) [NCBI Gene 407027] {aka MIR301, MIRN301, MIRN301A, mir-301a}, Il13ra1 (interleukin 13 receptor, alpha 1) [NCBI Gene 16164] {aka CD213a1, IL-13R-alpha-1, IL-13r[a], Il13ra, NR4}, IL7R (interleukin 7 receptor) [NCBI Gene 3575] {aka CD127, CDW127, IL-7R-alpha, IL-7Ralpha, IL7RA, IL7Ralpha}, CDKN2B-AS1 (CDKN2B and CDKN2A antisense cis and trans regulatory RNA 1) [NCBI Gene 100048912] {aka 66CTG, ANRIL, CDKN2B-AS, CDKN2BAS, NCRNA00089, PCAT12}, MIR29A (microRNA 29a) [NCBI Gene 407021] {aka MIRN29, MIRN29A, hsa-mir-29, hsa-mir-29a, miRNA29A, mir-29a}, MALAT1 (metastasis associated lung adenocarcinoma transcript 1) [NCBI Gene 378938] {aka HCN, LINC00047, NCRNA00047, NEAT2, PRO2853, miPEP-52}, MIR223 (microRNA 223) [NCBI Gene 407008] {aka MIRN223, miRNA223, mir-223}, DANCR (differentiation antagonizing non-protein coding RNA) [NCBI Gene 57291] {aka AGU2, ANCR, KIAA0114, SNHG13, lncRNA-ANCR}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, Lgr5 (leucine rich repeat containing G protein coupled receptor 5) [NCBI Gene 14160] {aka FEX, Gpr49}, IL23A (interleukin 23 subunit alpha) [NCBI Gene 51561] {aka IL-23, IL-23A, IL23P19, P19, SGRF}, MIR195 (microRNA 195) [NCBI Gene 406971] {aka MIRN195, miRNA195, mir-195}, MIR31 (microRNA 31) [NCBI Gene 407035] {aka MIRN31, hsa-mir-31, miR-31}, MIR146A (microRNA 146a) [NCBI Gene 406938] {aka MIRN146, MIRN146A, miR-146a, miRNA146A}, MEG3 (maternally expressed 3) [NCBI Gene 55384] {aka FP504, GTL2, LINC00023, Lnc-DLK1-35, NCRNA00023, PRO0518}, GDE1 (glycerophosphodiester phosphodiesterase 1) [NCBI Gene 51573] {aka 363E6.2, MIR16}, IFNG-AS1 (IFNG regulatory antisense RNA 1) [NCBI Gene 100885789] {aka GS1-410F4.2, NEST, Tmevpg1}, TJP1 (tight junction protein 1) [NCBI Gene 7082] {aka ZO-1}, H19 (H19 imprinted maternally expressed transcript) [NCBI Gene 283120] {aka ASM, ASM1, BWS, D11S813E, GMRSP, LINC00008}, MIR221 (microRNA 221) [NCBI Gene 407006] {aka MIRN221, miRNA221, mir-221}, MIR29B1 (microRNA 29b-1) [NCBI Gene 407024] {aka MIRN29B1, miR-29b, miRNA29B1, mir-29b-1}, Sox9 (SRY (sex determining region Y)-box 9) [NCBI Gene 20682] {aka 2010306G03Rik, mKIAA4243, mSox9}, Foxp1 (forkhead box P1) [NCBI Gene 108655] {aka 3110052D19Rik, 4932443N09Rik}, IL17RA (interleukin 17 receptor A) [NCBI Gene 23765] {aka CANDF5, CD217, CDw217, IL-17RA, IL17R, IMD51}, IL6ST (interleukin 6 cytokine family signal transducer) [NCBI Gene 3572] {aka CD130, CDW130, GP130, HIES4, HIES4A, HIES4B}, EIF4A3 (eukaryotic translation initiation factor 4A3) [NCBI Gene 9775] {aka DDX48, Fal1, MUK34, NMP265, NUK34, RCPS}, BTG1 (BTG anti-proliferation factor 1) [NCBI Gene 694] {aka APRO2}, MIR142 (microRNA 142) [NCBI Gene 406934] {aka MIRN142, mir-142}, MIR21 (microRNA 21) [NCBI Gene 406991] {aka MIRN21, hsa-mir-21, miR-21, miRNA21} - **Diseases:** injury (MESH:D014947), ischemia (MESH:D007511), TC (OMIM:275350), neurological disorders (MESH:D009461), intestinal diseases (MESH:D007410), carcinogenesis (MESH:D063646), IBS (MESH:D043183), barrier disorders (MESH:C536830), Inflammation (MESH:D007249), colorectal cancer (MESH:D015179), necrotizing (MESH:D009336), Dysfunction of IEH (MESH:C567703), I/R (MESH:D015427), CAC (MESH:D000083023), Colitis (MESH:D003092), immune dysregulation (OMIM:614878), colorectal adenocarcinoma (MESH:D003110), CD (MESH:D003424), NEC (MESH:D020345), celiac disease (MESH:D002446), IBD (MESH:D015212), enterocolitis (MESH:D004760), sepsis (MESH:D018805), Cancer (MESH:D009369), small bowel colitis (MESH:D003093), ulcerative (MESH:D014456) - **Chemicals:** LPS (MESH:D008070), glucose (MESH:D005947), lipid (MESH:D008055), AOM (MESH:D001397), fat (MESH:D005223), HGHF (-) - **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606] - **Mutations:** ATG9A ## Full text _Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12535046/full.md ## Figures 9 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12535046/full.md ## References 10 references — full list in the complete paper: https://tomesphere.com/paper/PMC12535046/full.md --- Source: https://tomesphere.com/paper/PMC12535046